1-(4-hydroxyphenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one | 939772-70-0

• 英文名称: 1-(4-hydroxyphenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one
• CAS: 939772-70-0
• 化学式: C₂₆H₃₄N₂O₃
• 分子量: 422.568
• InChiKey: ZDGKEJQYDRDVRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.67
• 重原子数：
  31.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.01
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  1-(4-hydroxyphenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one 在 sodium tetrahydroborate 作用下， 以100%的产率得到4-(1-hydroxy-2-{2-[3-(3-piperidin-1-yl-propoxy)-phenyl]-pyrrolidin-1-yl}-ethyl)-phenol
  参考文献：
  名称：

  Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

  摘要：

  A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.106
• 作为产物：
  描述：

  3-(3-chloro-propoxy)-benzoic acid ethyl ester 在 lithium aluminium tetrahydride 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 反应 146.5h， 生成 1-(4-hydroxyphenyl)-2-(2-(3-(3-(piperidin-1-yl)propoxy)phenyl)pyrrolidin-1-yl)ethan-1-one
  参考文献：
  名称：

  Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors

  摘要：

  A series of novel and potent pyrrolidino-tetrahydroisoquinolines with dual histamine H-3 antagonist/serotonin transporter inhibitor activity is described. A highly regio- and diastereoselective synthesis of the pyrrolidino-tetrahydroisoquinoline core involving acid mediated ring-closure of an acetophenone intermediate followed by reduction with NaCNBH3 was developed. In vitro and in vivo data are discussed. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.106